A banner year for AIDS therapy.
C
C
Meyer
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D053626:Atovaquone; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D009285:Naphthoquinones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017828:Rifabutin; D012294:Rifamycins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000935:Antifungal Agents; D000995:Antitubercular Agents; D009285:Naphthoquinones; D012294:Rifamycins; D017828:Rifabutin; D017964:Itraconazole; D016047:Zalcitabine; D007654:Ketoconazole; D053626:Atovaquone